Proteomics in Pleural Effusions

Sánchez-Otero, Nuria; Bielsa, Silvia; Porcel, José M.

doi:10.5152/pb.2012.14

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few MS-based studies have been conducted to characterize PE proteomes and to identify potential protein biomarkers of lung cancer [4] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] . Two studies are worth mentioning as they verified a larger group of potential biomarkers thru MRM use or assessed the results on a large patient set [26] , [27] .…”

Section: Introductionmentioning

confidence: 99%

A Multiplexed Cytokeratin Analysis Using Targeted Mass Spectrometry Reveals Specific Profiles in Cancer-Related Pleural Effusions

et al. 2016

View full text Add to dashboard Cite

Pleural effusion (PE), excess fluid in the pleural space, is often observed in lung cancer patients and also forms due to many benign ailments. Classifying it quickly is critical, but this remains an analytical challenge often lengthening the diagnosis process or exposing patients to unnecessary risky invasive procedures. We tested the analysis of PE using a multiplexed cytokeratin (CK) panel with targeted mass spectrometry–based quantitation for its rapid classification. CK markers are often assessed in pathological examinations for cancer diagnosis and guiding treatment course. We developed methods to simultaneously quantify 33 CKs in PE using peptide standards for increased analytical specificity and a simple CK enrichment method to detect their low amounts. Analyzing 121 PEs associated with a variety of lung cancers and noncancerous causes, we show that abundance levels of 10 CKs can be related to PE etiology. CK-6, CK-7, CK-8, CK-18, and CK-19 were found at significantly higher levels in cancer-related PEs. Additionally, elevated levels of vimentin and actin differentiated PEs associated with bacterial infections. A classifier algorithm effectively grouped PEs into cancer-related or benign PEs with 81% sensitivity and 79% specificity. A set of undiagnosed PEs showed that our method has potential to shorten PE diagnosis time. For the first time, we show that a cancer-relevant panel of simple-epithelial CK markers currently used in clinical assessment can also be quantitated in PEs. Additionally, while requiring less invasive sampling, our methodology demonstrated a significant ability to identify cancer-related PEs in clinical samples and thus could improve patient care in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

A Multiplexed Cytokeratin Analysis Using Targeted Mass Spectrometry Reveals Specific Profiles in Cancer-Related Pleural Effusions

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, most studies lack adequate sample sizes, are heterogeneous in the comparison groups and the proteomic technologies applied, and generally do not validate their findings. 22 The choice of an appropriate proteomic methodology depends on many factors, including the availability of resources and the number of samples to be processed. Rather than exploring putative biomarkers through complex or research-limited proteomic methodologies in a blinded strategy (i.e., the proteome to be investigated is not known), 23 , 24 we made use of a biochip array which allowed us to determine multiple prespecified protein biomarkers (guided strategy) from a single sample.…”

Section: Discussionmentioning

confidence: 99%